Condition
Superficial Siderosis
Total Trials
3
Recruiting
1
Active
1
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
1Total
Not Applicable (1)
Trial Status
Completed1
Not Yet Recruiting1
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT07098650RecruitingPrimary
Haemdall: Developing a Quantitative MRI Biomarker of Infratentorial Superficial Siderosis of the Central Nervous System
NCT04890808Not ApplicableNot Yet RecruitingPrimary
Therapeutic Antioxidant Supplementation
NCT01284127CompletedPrimary
Observational Study of Deferiprone (Ferriprox®) in the Treatment of Superficial Siderosis
Showing all 3 trials